Connor, Clark & Lunn Investment Management (CC&L)’s Amylyx Pharmaceuticals AMLX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.9M	Sell	721,002 -147,323	-17%	-$2.28M	0.02%	469
2026 Q1	$12.1M	Sell	868,325 -135,696	-14%	-$1.91M	0.03%	433
2025 Q4	$12.1M	Sell	1,004,021 -102,987	-9%	-$1.4M	0.03%	409
2025 Q3	$15M	Sell	1,107,008 -47,477	-4%	-$447K	0.05%	324
2025 Q2	$7.4M	Sell	1,154,485 -45,206	-4%	-$220K	0.03%	476
2025 Q1	$4.25M	Sell	1,199,691 -63,662	-5%	-$227K	0.02%	539
2024 Q4	$4.78M	Buy	1,263,353 +382,608	+43%	+$1.8M	0.02%	493
2024 Q3	$2.85M	Buy	880,745 +258,818	+42%	+$582K	0.01%	590
2024 Q2	$1.18M	Buy	621,927 +95,239	+18%	+$185K	0.01%	812
2024 Q1	$1.5M	Buy	526,688 +270,082	+105%	+$3.53M	0.01%	759
2023 Q4	$3.78M	Buy	256,606 +132,151	+106%	+$2.03M	0.02%	507
2023 Q3	$2.28M	Buy	+124,455	New	+$2.63M	0.01%	582

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AMLX Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Amylyx Pharmaceuticals (AMLX) stake by 17% in Q2 2026, selling an estimated $2.28M and leaving 721,002 shares worth $12.9M. The position accounts for 0.02% of the portfolio, ranked #469.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AMLX in Q3 2023 and has held it in 12 quarters since. The position peaked at $15M in Q3 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 721,002 shares of Amylyx Pharmaceuticals worth $12.9M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 147,323 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $2.28M.
Amylyx Pharmaceuticals made up 0.02% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #469 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Amylyx Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Amylyx Pharmaceuticals position peaked at $15M in Q3 2025.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.